FibroBiologics, Inc. Common StockFBLGNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank40
3Y CAGR-18.7%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-18.7%/yr
Annual compound
Percentile
P40
Within normal range
vs 3Y Ago
0.5x
Contraction
Streak
3 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 64.45% |
| 2024 | 90.20% |
| 2023 | 106.45% |
| 2022 | 120.15% |
| 2021 | -22.12% |
| 2020 | 0.00% |